Bioxcel Therapeutics Senior VP Wiley Transitions to Consultant

Bioxcel Therapeutics ( (BTAI) ) has provided an update.

Matthew Wiley, Senior Vice President and Chief Commercial Officer of BioXcel Therapeutics, has agreed to step down from his role effective October 2, 2024, and transition to a consultancy role. He will receive severance benefits including a pro-rated bonus for 2024, nine months of his base salary, and COBRA premium reimbursements. Additionally, Wiley will consult for BioXcel at $330 per hour plus expenses until December 31, 2024, unless the agreement is terminated earlier.

For an in-depth examination of BTAI stock, go to TipRanks’ Stock Analysis page.